当前位置: X-MOL 学术Clin. Infect. Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design
Clinical Infectious Diseases ( IF 8.2 ) Pub Date : 2018-05-21 , DOI: 10.1093/cid/ciy312
John M McLaughlin 1 , Qin Jiang 1 , Raul E Isturiz 1 , Heather L Sings 1 , David L Swerdlow 1 , Bradford D Gessner 1 , Ruth M Carrico 2 , Paula Peyrani 2 , Timothy L Wiemken 3 , William A Mattingly 2 , Julio A Ramirez 2 , Luis Jodar 1
Affiliation  

Following universal recommendation for use of 13-valent pneumococcal conjugate vaccine (PCV13) in US adults aged ≥65 years in September 2014, we conducted the first real-world evaluation of PCV13 vaccine effectiveness (VE) against hospitalized vaccine-type community-acquired pneumonia (CAP) in this population.

中文翻译:

13价肺炎球菌结合疫苗对美国老年人获得社区获得性肺炎住院治疗的有效性:试验阴性设计

继2014年9月在美国65岁以上的成年人中普遍推荐使用13价肺炎球菌结合疫苗(PCV13)之后,我们对PCV13疫苗对医院接种的社区获得性肺炎的有效性进行了首次真实评估(CAP)。
更新日期:2018-05-21
down
wechat
bug